This article is more than 5 years old. Information may no longer be current.
First patient treated in trial of novel cell therapy
Click Here to Manage Email Alerts
The first patient has been treated with a cell-based therapy for the treatment of ischemic HF as a part of a pivotal phase 3 trial, according to a press release from Johns Hopkins Medicine, the Maryland Stem Cell Research Fund and BioCardia Inc.
The therapy (CardiAMP, BioCardia Inc.) involves the delivery of a high dose of a patient’s own bone marrow cells into the areas of cardiac dysfunction. According to the release, this could stimulate the body’s natural healing mechanism after MI.
“This cell-based therapy offers great potential for [patients with HF],” Cardiology Today Chief Medical Editor Carl Pepine, MD, MACC, professor and former chief of cardiovascular medicine at the University of Florida, Gainesville, and national co-principal investigator of the CardiAMP trial, said in the release. “We look forward to validating the impact of the therapy on patients’ quality of life and functional capacity in this important study.”
The CardiAMP trial is a phase 3, multicenter, randomized, double blind study of up to 260 patients with NYHA Class II or III HF as a result of previous MI. The primary endpoint in the trial is improvement in 6-minute walk distance at 12 months after treatment.